
Region:North America
Product Code:GDPH406158D
September 2018
33
Summary
Aviragen Therapeutics Inc (Aviragen) is a pharmaceutical company that carries out anti-infective drug discovery, development and its commercialization to treat respiratory diseases. It has four product candidates in clinical development which address viral infections, namely, vapendavir, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus; BTA074, a Phase 2 topical antiviral treatment for genital warts; BTA585, an oral fusion protein inhibitor that Aviragen is developing for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a long-acting neuraminidase inhibitor for influenza A and B infections. The Company also has a preclinical RSV non-fusion inhibitor program for its F-protein inhibitor BTA585. Aviragen is headquartered in Alpharetta, Georgia, the US.
Aviragen Therapeutics Inc (AVIR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aviragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 12
Merger 13
Aviragen Therapeutics Completes Merger With Vaxart 13
Nabi Biopharma Completes Merger With Biota 14
Licensing Agreements 16
Aviragen Therapeutics Enters into Licensing Agreement with Georgia State University Research Foundation 16
Equity Offering 17
Biota Pharma Plans to Raise USD25 Million in Public offering of Shares 17
Biota Pharma Completes Public Offering Of shares For USD 29 Million 18
Asset Transactions 20
Spero Therapeutics Acquires Antibiotic Assets from Biota Pharma (Aviragen Therapeutics) 20
TAXIS Pharma Acquires Antimicrobial Drugs from Biota Pharma 21
Acquisition 22
Biota Pharma Acquires Anaconda Pharma for up to USD38 Million 22
Aviragen Therapeutics Inc-Key Competitors 23
Aviragen Therapeutics Inc-Key Employees 24
Aviragen Therapeutics Inc-Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 02, 2017: Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results 26
Aug 31, 2017: Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results 28
May 04, 2017: Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results 29
Feb 02, 2017: Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results 30
Other Significant Developments 32
Apr 04, 2017: Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.